Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Post by wildbird1on Apr 07, 2019 12:01pm
224 Views
Post# 29593591

LifeX influence...

LifeX influence...As a complement to my last post...J.Tripp said ''I will draw comparaison to a very successful competitor in the MarketPlace. They do very large number of tests at this particular point, they have very large number, in fact an absolutely huge number of people that they say prescribers. When you average their number out, you see that each prescriber (small practice) give them about one and a quarter tests per quarter. That is not really were you want to go. I think they have over 400 reps. They spend a huge amount of money, they make decent money, but they're a long way from breakeven, long way from profitability''

Check this link once more and you will realise that J.Tripp is talking about Exact Science Colorectal Poop Test(Cologuard).
https://www.fool.com/investing/2018/01/10/3-slides-that-paint-a-great-picture-for-exact-scie.aspx

What J.Tripp is trying to say is that GEN will get to profitability using a much faster path, and at a much lower cost than Exact Science.

Look like that since GEN new partner LifeX came on board, GEN has changed its strategy, and seem to be making all the right moves.
To know more about LifeX mission read some of Nailbiter1 very good posts on LifeX.

Do your own DD, do not rely on my posts or the posts of a guy that pretend to be a Know-It-All speculator.

You my want to read the Earnings Transcript, print it on paper and read it a few time, that way it's much easier to comprehend the full meaning of that transcript, and you will realise what is really coming in the next few months.
https://seekingalpha.com/article/4252675-genenews-limited-gnwsf-ceo-james-howard-tripp-q4-2018-results-earnings-call-transcript

Knowledge is power.

Have a nice day.

Bullboard Posts